4538 Fuso Pharmaceutical Industries,Ltd. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4538

TSE Prime

Fuso Pharmaceutical Industries,Ltd.

2,432

JPY

(0.00%)

Mar 13, 3:30 pm JST

15.25

USD

Mar 13, 2:30 am EDT

Result

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2022	49,632	1,924	1,996	1,483	169.1	60	May 11, 2022	J-GAAP
Mar, 2023	51,015	2,206	2,215	1,605	183.1	70	May 10, 2023	J-GAAP
Mar, 2024	55,407	1,964	1,868	1,377	160.0	70	May 10, 2024	J-GAAP
Mar, 2025	60,563	4,131	3,780	-3,288	-385.0	82	May 9, 2025	J-GAAP
Mar, 2026 Guidance	61,500	3,400	3,300	2,300	269.4	90	May 9, 2025	J-GAAP
YoY	+1.5%	-17.7%	-12.7%	－	－

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Mar, 2021	May 12, 2020	48,800	1,600	1,500	1,100	60	J-GAAP
	Nov 10, 2020	49,200	2,800	2,600	1,900	60	J-GAAP
Results	May 12, 2021	49,251	2,351	2,227	1,607	60	J-GAAP
Mar, 2022	May 12, 2021	Available in future release
	Nov 11, 2021
Results	May 11, 2022
Mar, 2023	May 11, 2022
	Nov 9, 2022
	Feb 10, 2023
Results	May 10, 2023
Mar, 2024	May 10, 2023
Results	May 10, 2024
Mar, 2025	May 10, 2024
	Nov 11, 2024
Results	May 9, 2025
Mar, 2026	May 9, 2025	61,500	3,400	3,300	2,300	90	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Mar, 2001	45,323	+0.2	Available in future release
Mar, 2002	44,226	-2.4
Mar, 2003	41,926	-5.2
Mar, 2004	41,352	-1.4
Mar, 2005	41,919	+1.4
Mar, 2006	42,664	+1.8
Mar, 2007	43,167	+1.2
Mar, 2008	43,991	+1.9
Mar, 2009	45,901	+4.3
Mar, 2010	46,560	+1.4
Mar, 2011	47,469	+2.0
Mar, 2012	44,358	-6.6
Mar, 2013	48,612	+9.6
Mar, 2014	49,098	+1.0
Mar, 2015	47,042	-4.2
Mar, 2016	45,752	-2.7
Mar, 2017	46,782	+2.3
Mar, 2018	45,900	-1.9
Mar, 2019	46,074	+0.4
Mar, 2020	46,902	+1.8
Mar, 2021	49,251	+5.0
Mar, 2022	49,632	+0.8
Mar, 2023	51,015	+2.8
Mar, 2024	55,407	+8.6
Mar, 2025	60,563	+9.3
Mar, 2026 Guidance	61,500	+1.5	3,400	-17.7	3,300	-12.7	269.4	－

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Mar, 2024	55,407	1,964	3.54	3.81	1.86	0.75	160.0
Mar, 2025	60,563	4,131	6.82	-9.43	-4.17	0.77	-385.0
Mar, 2026 Guidance	61,500	3,400	5.53	6.64	2.57	0.69	269.4

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	60,563	4,709	4,524	4,871	538.1
Fiscal Year	Mar, 2025	Mar, 1989	Mar, 1990	Mar, 2013	Mar, 2013

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2022	25,644	921	816	587	67.0	40	May 10, 2023	J-GAAP
Oct - Mar, 2023	27,983	865	770	660	76.7	35	May 10, 2024	J-GAAP
Oct - Mar, 2024	30,824	1,697	1,637	-4,823	-564.7	42	May 9, 2025	J-GAAP
Oct - Mar, 2025 Guidance	30,271	2,153	2,169	1,469	172.1	45	Nov 10, 2025	J-GAAP
YoY	-1.8%	+26.9%	+32.5%	－	－

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Mar, 2023	2,206	1,480	2,853	-1,373	-813	8,014	11.06	J-GAAP
Mar, 2024	1,964	-2,909	627	-3,536	14	5,120	6.75	J-GAAP
Mar, 2025	4,131	-6,473	-3,305	-3,168	7,618	6,264	7.66	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Dec, 2023	42,830	1,843	1,829	1,227	141.9	97.9	Feb 13, 2024	J-GAAP
Apr - Dec, 2024	46,659	3,633	3,341	2,402	281.3	88.4	Feb 10, 2025	J-GAAP
Apr - Dec, 2025	48,265	2,367	2,216	1,684	197.2	67.2	Feb 12, 2026	J-GAAP
YoY	+3.4%	-34.8%	-33.7%	-29.9%	-29.9%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jan - Mar, 2024	12,577	121	39	150	17.4	1.0	May 10, 2024	J-GAAP
Apr - Jun, 2024	14,622	1,150	909	632	74.1	7.9	Aug 8, 2024	J-GAAP
Jul - Sep, 2024	15,117	1,284	1,234	903	105.7	8.5	Nov 11, 2024	J-GAAP
Oct - Dec, 2024	16,920	1,199	1,198	867	101.5	7.1	Feb 10, 2025	J-GAAP
Jan - Mar, 2025	13,904	498	439	-5,690	-666.2	3.6	May 9, 2025	J-GAAP
Apr - Jun, 2025	15,503	596	647	462	54.1	3.8	Aug 8, 2025	J-GAAP
Jul - Sep, 2025	15,726	651	484	369	43.3	4.1	Nov 10, 2025	J-GAAP
Oct - Dec, 2025	17,036	1,120	1,085	853	99.9	6.6	Feb 12, 2026	J-GAAP
YoY	+0.7%	-6.6%	-9.4%	-1.6%	-1.6%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Jan - Mar, 2021	11,039	+3.4	Available in future release
Apr - Jun, 2021	12,599	+1.4
Jul - Sep, 2021	12,367	-1.1
Oct - Dec, 2021	13,305	+0.2
Jan - Mar, 2022	11,361	+2.9
Apr - Jun, 2022	12,367	-1.8
Jul - Sep, 2022	13,004	+5.2
Oct - Dec, 2022	13,848	+4.1
Jan - Mar, 2023	11,796	+3.8
Apr - Jun, 2023	13,507	+9.2
Jul - Sep, 2023	13,917	+7.0
Oct - Dec, 2023	15,406	+11.3
Jan - Mar, 2024	12,577	+6.6
Apr - Jun, 2024	14,622	+8.3
Jul - Sep, 2024	15,117	+8.6
Oct - Dec, 2024	16,920	+9.8
Jan - Mar, 2025	13,904	+10.6
Apr - Jun, 2025	15,503	+6.0
Jul - Sep, 2025	15,726	+4.0
Oct - Dec, 2025	17,036	+0.7	1,120	-6.6	1,085	-9.4	99.9	-1.6

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	17,036	1,284	1,234	3,184	351.7
Fiscal Year	Dec, 2025	Sep, 2024	Sep, 2024	Dec, 2012	Dec, 2012

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Mar, 2023	4,064.76	49.2	72,466	35,649	15,811	0.32	May 10, 2023	J-GAAP
Mar, 2024	4,290.55	48.4	75,802	36,661	16,541	0.35	May 10, 2024	J-GAAP
Mar, 2025	3,869.10	40.4	81,729	33,043	12,612	0.64	May 9, 2025	J-GAAP
Apr - Dec, 2025	ー	38.7	89,449	34,655	13,553	0.86	Feb 12, 2026	J-GAAP

Fuso Pharmaceutical Industries,Ltd.(4538) Financial Results